Articles tagged with Prostate Cancer
Researchers have developed a new mouse model for metastatic prostate cancer, called RapidCaP, which reveals a specific role for Myc as a driver of metastasis in prostate cancer. The study suggests that targeting the Myc gene may provide a new approach to cure incurable prostate cancer.
A new study published in the Journal of Urology reports that prostate cancer patients treated with androgen deprivation therapy (ADT) experienced changes in mental and emotional well-being during treatment, with no significant decline in emotional quality of life two years after treatment. Investigators recommend counseling men about p...
Research suggests that walking at a brisk pace prior to diagnosis may improve prostate cancer outcomes by having more regularly shaped blood vessels. Men with faster walking paces had 8% more regularly shaped blood vessels compared to those with slower paces.
A study of Icelandic men found that higher melatonin levels were associated with a 75% reduced risk for developing advanced prostate cancer. Men who reported sleep problems had lower melatonin levels, suggesting the importance of maintaining a stable sleep-wake cycle.
Researchers at Penn State will receive $651,000 to create a method for identifying a prostate cancer-specific drug and developing a biodegradable nanoparticle capable of targeting the disease. The goal is to create an alternative to chemotherapy with reduced side effects.
A research group at Biocenter Oulu in Finland has identified a mechanism related to a transcription factor that binds strongly onto a particular SNP variant, initiating a genetic programme enhancing prostate cancer proliferation and metastasis. The study used DNA samples from tens of thousands of prostate cancer patients and healthy me...
Researchers developed a nomogram to predict likelihood of overdiagnosis based on age, PSA level, and Gleason score. The tool aims to help patients and clinicians make informed decisions about treatment options.
A study from the University of Illinois Chicago found that fetal exposure to BPA increases the risk for prostate cancer later in life. Human prostate tissue is susceptible to BPA, which mimics estrogen and has been linked to several cancers.
A new nomogram developed by Roman Gulati et al. estimates the likelihood of overdiagnosis for screen-detected prostate cancers, considering patient age, Gleason score, and PSA level at diagnosis. The model predicts risks ranging from 2.9% to 88.1% depending on individual characteristics.
A study published in Oncogene found that androgens hijack the AMPK signaling cascade to increase prostate cancer cell growth. This metabolic switch has significant implications for understanding early and late-stage prostate cancer progression.
Researchers will investigate racial and ethnic differences in IRDS-positive tumors prevalent in African-Americans to improve outcomes for patients with treatment-resistant prostate cancer. The study aims to identify new management and treatment options for this aggressive disease.
A Mayo Clinic-led study found that pain drugs used in prostate gland removal may be linked to cancer outcomes, as they can suppress the immune system's ability to fight cancer cells. The research suggests that a specific technique using opioids may reduce the risk of cancer recurrence and mortality.
A new optical sensor created at MIT can track zinc within cells, shedding light on its functions and helping researchers study zinc trafficking in prostate cells. The sensor supports the theory that cancerous prostate cells banish zinc from mitochondria to produce extra energy.
A study published online in Cancer found that increased inflammation in the prostate gland may predict a reduced risk of developing prostate cancer. The study's findings suggest that biopsies performed on prostates with high inflammation levels may indicate a lower risk for subsequent cancer detection.
Researchers have identified a potential biological factor contributing to racial disparities in prostate cancer incidence and mortality. Advanced glycation end-products (AGEs) accumulate in African-American men with prostate cancer, promoting inflammation and cancer progression. AGE levels correlated with receptor for AGE (RAGE), sugge...
Researchers identified a biomarker for prostate cancer recurrence, revealing that patients with CD151free protein have cancer recur earlier than those without. This discovery may aid in determining patient care and predicting disease progression.
Researchers found that 53% of men with ERG-positive HGPIN biopsies developed invasive prostate cancer, compared to 35% of those with ERG-negative biopsies. The discovery may help physicians monitor men at higher risk for cancer development and reduce unnecessary future biopsies.
A new study found that men with a specific genetic mutation are more than 50% likely to die from prostate cancer if they're overweight or obese. The researchers analyzed data on 1,243 participants and discovered that obesity was linked to higher levels of insulin and growth factor receptors in tumors containing the mutation.
Researchers at Henry Ford's Vattikuti Urology Institute found instances of ureteral injury in 6,442 patients who underwent robotic prostatectomy. Patient characteristics such as infection history, abdominal surgery, and enlarged prostate glands may forewarn such damage.
Men with prostate cancer who followed a low-fat fish oil diet had lower levels of pro-inflammatory substances in their blood and a lower cell cycle progression score compared to those on a Western diet. The study suggests that altering the diet may favorably affect prostate cancer biology.
Researchers have identified large oncosomes as a potential indicator of patients with more aggressive, treatment-resistant disease. The study also found that microRNA in these vesicles can influence tumor progression.
Researchers discovered that selective inhibition of nuclear export protein CRM1 can reactivate tumor suppressor proteins in cells, leading to cancer cell death. This approach shows promise for treating advanced prostate cancers.
Researchers developed predictive models to forecast genito-urinary (GU) toxicity and erectile dysfunction in prostate cancer patients after high-dose radiotherapy. Smoking and dosimetric factors were key predictors of acute urinary symptoms, with the model confirmed by a larger cohort analysis.
A new study suggests that treatment of pelvic nodes individualized by including sentinel nodes can be easily integrated into an IMRT-based strategy, correctly covering individual pelvic nodes without nodal recurrence. The study's findings indicate low toxicity and efficacy, justifying further evaluation.
Researchers found that geranylgeraniol suppressed human DU145 prostate carcinoma cell viability via cell cycle arrest at the G1 phase and apoptosis initiation. The compound also down-regulated HMG CoA reductase, a key enzyme in the mevalonate pathway.
Researchers explore genetic and epigenetic factors contributing to racial disparities in prostate cancer risk and progression, focusing on MicroRNAs as potential biomarkers.
A study published in Physics in Medicine and Biology found that endorectal balloon placement errors can reduce radiation dose coverage, leading to uneven targeting of cancerous areas. Image guidance is crucial to ensure accurate prostate positioning.
A Polish study has developed a new imaging modality using Magnetic Resonance Imaging-Ultrasound (MRIUS) to guide prostate biopsies, yielding higher sensitivity rates compared to traditional TRUS biopsies. The technology, which fuses MRI with TRUS images, allows for real-time guidance of targeted biopsies in office settings.
A pilot study shows that older patients who practiced Qigong experienced significant declines in fatigue and distress. The mind-body activity, which combines slow movements with deep breathing and meditation, was found to be an effective nonpharmacological intervention for managing prostate cancer-related fatigue.
A Kaiser Permanente study found that men diagnosed with prostate cancer who were overweight or obese at diagnosis were more likely to die from the disease. Men with high Gleason scores had the strongest correlation between body mass index and death, suggesting weight loss could prolong survival.
Researchers analyzed genealogical and medical records of Utah males, identifying distinct Y chromosomes associated with a significant excess risk of prostate cancer. The study found that nearly 73 out of 1,000 Y chromosome groups had a higher incidence of prostate cancers than expected.
Researchers tracked lethal prostate cancer to determine the clonal origin of a patient's deadly disease. Using tissue samples, they identified the primary tumor site of the lethal clone, revealing that it originated from a small, low-grade foci rather than the larger high-grade region.
A comprehensive review of Medicare claims found that nearly all the increase in IMRT for prostate cancer was due to self-referral, leading to unnecessary radiation therapy. Self-referring urologists increased IMRT use by 146%, while non-self-referrers remained unchanged.
A new online program developed by Thomas Jefferson University researchers has shown that more patients choose active surveillance over therapy when presented with pros and cons of treatment options. The program helps patients clarify their treatment preferences and discuss options with the clinical team.
A new study by University of Pennsylvania researcher Robert Aronowitz highlights the flaws in prostate cancer screening measures, citing a 1950s study that showed invasive procedures were often performed without solid evidence. Millions of men have undergone PSA tests, which can lead to unnecessary treatments and detrimental effects.
A study from University of Texas Medical Branch found that more than 40% of men over 75 undergo PSA screening, despite no medical organization recommending it for this age group. The researchers suggest that decision-making by primary care physicians is a major reason for the continued high PSA rate.
A recent study found that detecting changes in circulating tumor cells (CTC) may be more accurate than tracking prostate-specific antigen (PSA) levels to predict treatment outcomes in patients with castration-resistant prostate cancer. The study showed a favorable change in CTC detection occurred in over half of patients during chemoth...
A study by Yale researchers found that Medicare spent $447 million annually on PSA-based screenings for prostate cancer, with most of it going to men over 75. The cost variation was mainly due to follow-up tests, not the use of the PSA itself.
Researchers estimate that routine PSA testing can lead to increased impotence and incontinence cases, as well as additional prostate cancer diagnoses. However, the difference in death rates between screened and unscreened men is relatively small, with only 0.07 more deaths attributed to screening.
Researchers found that men with variable telomere length in cancer cells and shorter telomeres in stromal cells were more likely to develop metastatic disease and die sooner from their prostate cancer. This combination could be a marker for prostate cancer prognosis.
Researchers found that unstable chromosomes with breaks at common fragile sites are associated with a less favorable response to radiation therapy and surgery in prostate cancer patients. These abnormalities are often linked to DNA instability, which is characteristic of cancer cells.
Cancer researchers at UC San Diego isolated and characterized early-stage prostate cancer cells, which may drive recurrent disease. The study suggests that these cells could be targeted for new treatments, potentially reducing cancer progression.
A shorter course of androgen suppression therapy prior to radiation therapy yields favorable outcomes and fewer adverse effects for intermediate-risk prostate cancer patients. The study confirmed a disease-specific-survival rate of 95 percent when patients received fewer weeks of neoadjuvant total androgen suppression.
A secondary analysis of the historic RTOG 9202 prostate cancer trial found no additional benefits with long-term hormonal therapy compared to short-term therapy in intermediate-risk patients. The study suggests that administering less treatment can reduce side effects and healthcare costs without compromising survival rates.
A new study by Moffitt Cancer Center aims to investigate alternative screening methods and chemoprevention interventions for African-American and black men with prostate cancer. Researchers are also exploring the safety and effectiveness of isoflavones, a botanical agent, in reducing prostate cancer risk in this high-risk population.
A study published in the Journal of the National Cancer Institute found that proteins delivering leucine to prostate cancer cells are therapeutic targets. Inhibition of these proteins inhibits nutrient signaling pathways and over 100 metastasis-related genes, leading to cell cycle inhibition and reduced tumor growth.
The National Cancer Institute has awarded a five-year, $11.3 million competitive grant renewal to Fred Hutchinson Cancer Research Center to lead the Pacific Northwest Prostate Cancer SPORE consortium. The consortium aims to unravel molecular mechanisms and develop precision-medicine approaches for prostate cancer treatment.
A pilot study found that comprehensive lifestyle changes increased telomere length by an average of 10%, while control group telomeres decreased by 3%. The study suggests that such lifestyle changes may significantly reduce the risk of diseases and premature mortality.
The Wistar Institute has received a $1.5 million grant from the US Department of Defense to prepare its potential new prostate cancer drug Gamitrinib for trial in humans. The three-year grant will cover the costs of developing the data necessary to allow Gamitrinib's use in the clinic.
A new three-gene biomarker can accurately predict which low-risk prostate cancers will become aggressive, helping doctors determine whether men need active surveillance or invasive treatment. The test has shown promising results in a retrospective study of 43 patients, and further clinical trials are planned.
A recent study by researchers at Fred Hutchinson Cancer Center has discovered a link between mutations in the BTNL2 gene and an increased risk of developing prostate cancer. The study found that rare variants of this gene are associated with both hereditary and sporadic cases of prostate cancer.
A genetic mutation in the androgen-synthesizing enzyme 3βHSD1 enables tumors to produce their own supply of androgens, leading to the growth of castration-resistant prostate cancer. This discovery could lead to the development of biomarkers and targeted therapies for personalized medicine.
Researchers found a 59% reduced risk of prostate cancer recurrence and/or progression in men who consumed four or more cups of coffee per day. The study suggests that bioactive compounds in coffee may have anti-inflammatory and antioxidant effects, but further research is needed to understand the mechanisms underlying the results.
A new GE technology uses pyruvate levels to detect prostate tumors in real time, providing a safe and non-invasive way to assess cancer progression. The technology has shown promising results in a clinical study of 31 patients with prostate cancer.
A long-term study confirms that finasteride reduces the risk of prostate cancer by 43% in low-grade tumors and by 30% overall. This means thousands of men can avoid unnecessary treatments and burden on society.
A study found that prostate cancer aggressiveness is established at tumor formation and does not change over time. The proportion of patients diagnosed with advanced-stage cancers decreased by more than six-fold after widespread PSA screening, while high Gleason grade cancers remained stable.
A collaborative study identifies PRNCR1 and PCGEM1 as long non-coding RNAs that activate androgen receptors, leading to cancer growth and resistance to treatment. The study provides a new target for therapies and offers hope for developing more effective treatments for aggressive prostate cancer.
Researchers identified Skp2 inhibitor that blocks malignancy-promoting effects, shrinks tumors in preclinical studies. The compound suppresses prostate cancer stem cells, which play a role in cancer initiation and progression.
A new therapeutic approach to treating prostate cancer has been identified through a study on the FoxM1 protein. Depletion of FoxM1 in prostate epithelial cells inhibits tumor cell proliferation, metastasis, and new blood vessel formation.
Researchers at Sanford-Burnham Medical Research Institute have identified a novel mechanism of action for SMIP004, which specifically kills prostate cancer cells by interfering with mitochondrial function. The compound's effects were found to be particularly promising for treating castration-resistant prostate cancer.